• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Eli Lilly

Lilly to submit once-weekly insulin for regulatory review this year following strong clinical results

June 22, 2025 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) today announced positive safety and efficacy data for its investigational once-weekly insulin efsitora alfa (efsitora). The QWINT-1, QWINT-3 and QWINT-4 Phase 3 clinical trials evaluated efsitora in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance Tagged With: ADA 2025, Eli Lilly, Eli Lilly & Co.

Lilly gets nod to market locally manufactured insulin in Egypt

December 17, 2024 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) announced today that the Egyptian Drug Authority approved insulin glargine manufactured in partnership with Eva Pharma. The companies launched their collaboration in 2022 to deliver a sustainable supply of high-quality, affordable human and analog insulin. It wants to bring insulin to at least 1 million people annually living with diabetes in low- to […]

Filed Under: Uncategorized Tagged With: Eli Lilly, Eva Pharma

Eli Lilly has positive once-weekly insulin data

September 5, 2024 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) today announced positive results from phase 3 clinical trials evaluating its once-weekly insulin efsitora alfa. The Indianapolis-based pharmaceutical giant evaluated its once-weekly insulin in insulin-naïve adults in the QWINT-1 study. These adults have type 2 diabetes and are using basal insulin for the first time. Additionally, Eli Lilly’s QWINT-3 trial looked at […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Pharmaceuticals Tagged With: Eli Lilly, Eli Lilly & Co.

Eli Lilly acquires new injectable medicine manufacturing plant

April 22, 2024 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) announced today that it agreed to acquire a manufacturing facility from sterile manufacturer Nexus. Buying the FDA-approved facility in Pleasant Prairie, Wisconsin, further expands Lilly’s global parenteral (injectable) manufacturing network. It also supports increased demand for the company’s medicines, Lilly said in a news release. The company expects that production at the […]

Filed Under: Business/Financial News, Pharmaceuticals Tagged With: Eli Lilly, Eli Lilly & Co.

Lilly to acquire Sigilon, cell therapy for treating diabetes

June 29, 2023 By Sean Whooley

Eli Lilly Sigilon logo

Eli Lilly (NYSE:LLY) announced today that it entered a definitive agreement to acquire biopharmaceutical company Sigilon. Cambridge, Massachusetts-based Sigilon seeks to develop functional cures for patients with a range of acute and chronic diseases. The two companies have collaborated since 2018 to develop encapsulated cell therapies, including SIG-002. These therapies aim to treat type 1 […]

Filed Under: Business/Financial News, Diabetes, Featured, Mergers & Acquisitions, Pharmaceuticals, Stem Cells Tagged With: Eli Lilly, Eli Lilly & Co., sigilontherapeutics

Eli Lilly, ADA and Red Sox star Adam Duvall launch insulin affordability awareness program

June 20, 2023 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) and the American Diabetes Association partnered with MLB player Adam Duvall to increase insulin affordability awareness. Lilly, ADA and Duvall agreed to launch a nationwide effort to highlight affordable insulin for all living with diabetes. This effort comes on the heels of Lilly’s announcement in March that it planned to significantly cut […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured Tagged With: American Diabetes Association, Eli Lilly, Eli Lilly & Co.

Eli Lilly is cutting the price of insulin by 70%

March 1, 2023 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) announced today that it plans to execute price reductions of 70% for its most commonly prescribed insulins. Indianapolis-based Lilly also plans to expand its Insulin Value Program. This caps patient out-of-pocket costs at $35 or less per month. The company said it took these actions to “help Americans” in a “complex healthcare […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Eli Lilly, Eli Lilly & Co.

The year ahead in diabetes care: what to expect in 2023

January 25, 2023 By Sean Whooley

Walmart Health Virtual Care Diabetes Program

After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023. Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more. You can read all about the biggest diabetes stories […]

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Mergers & Acquisitions, Patient Monitoring, Pharmaceuticals, Regulatory/Compliance, Research & Development, Technology Tagged With: abbott, Beta Bionics, Dexcom, Diabetes, Eli Lilly, embecta, eoflow, Insulet, Medtronic, Novo Nordisk, oramedpharmaceuticals, Senseonics, Tandem Diabetes Care, Ypsomed

Eli Lilly to invest $450M in North Carolina diabetes treatment manufacturing facility

January 24, 2023 By Sean Whooley

Eli Lilly

Eli Lilly (NYSE:LLY) announced today that it plans to invest an additional $450 million at a North Carolina manufacturing facility. Lilly expects the investment to create at least 100 new jobs at the Research Triangle Park, North Carolina, plant. Its expansion includes additional parenteral filling, device assembly and packaging capacity. Indianapolis-based Lilly said this expansion […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Eli Lilly, Eli Lilly & Co.

Eli Lilly discontinues Ypsomed collaboration to pursue its own U.S. insulin pump offering

December 9, 2022 By Sean Whooley

Ypsomed Eli Lilly

Ypsomed announced today that Eli Lilly (NYSE:LLY) elected to stop their joint project to enter the U.S. insulin pump market. In November 2020, the companies entered into a commercialization agreement. The agreement entailed registering and commercializing Ypsomed’s YpsoPump under Lilly’s branding in the U.S. Ypsomed said that, over the past two years, it customized its […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Technology Tagged With: Eli Lilly, Eli Lilly & Co., Ypsomed

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS